- Home
- ACLX vs NUVB Comparison
ACLX vs NUVB Comparison
Compare ACLX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLX | NUVB |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.9B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACLX | NUVB |
|---|---|---|
| Price | $68.61 | $5.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $113.75 | $11.44 |
| AVG Volume (30 Days) | 868.4K | ★ 5.4M |
| Earning Date | 02-27-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,898,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $636.92 |
| Revenue Next Year | $309.32 | $191.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $47.86 | $1.54 |
| 52 Week High | $94.07 | $9.75 |
Technical Indicators
Market Signals| Indicator | ACLX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 41.59 |
| Support Level | $66.12 | $5.49 |
| Resistance Level | $70.34 | $6.22 |
| Average True Range (ATR) | 2.60 | 0.36 |
| MACD | 0.20 | 0.10 |
| Stochastic Oscillator | 83.43 | 63.64 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.